The Physiology of the Gastric Parietal Cell | Physiological Reviews
Figure 1 | Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438) | SpringerLink
Figure 2 from Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438) | Semantic Scholar
Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases - ScienceDirect
Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders - Abdel‐Aziz - 2021 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases - ScienceDirect
Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action - ScienceDirect
Phathom Could See Substantial Upside With 2 Upcoming Phase 3 Readouts (PHAT) | Seeking Alpha
JCM | Free Full-Text | Peptic Ulcer Disease: A Brief Review of Conventional Therapy and Herbal Treatment Options | HTML
phat-10k_20201231.htm
Vonoprazan-based therapy for <i>Helicobacter pylori</i> eradication: experience and clinical evidence. - Abstract - Europe PMC
Impact of Acid-Reducing Agents on Gastrointestinal Physiology and Design of Biorelevant Dissolution Tests to Reflect These Changes - Journal of Pharmaceutical Sciences
Potassium-Competitive Acid Blocker: Novel Class of Anti- Acid Drug
Mode of action of P-CABs as compared with PPIs. The PPIs convert to... | Download Scientific Diagram
Impact of Acid-Reducing Agents on Gastrointestinal Physiology and Design of Biorelevant Dissolution Tests to Reflect These Changes - Journal of Pharmaceutical Sciences
Vocinti Full Prescribing Information, Dosage & Side Effects | MIMS Malaysia
Figure 10 from Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438) | Semantic Scholar
Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease? - Abstract - Europe PMC
Phathom Could See Substantial Upside With 2 Upcoming Phase 3 Readouts (PHAT) | Seeking Alpha
Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. - Abstract - Europe PMC
The binding selectivity of vonoprazan (TAK‐438) to the gastric H+,K+‐ATPase - Scott - 2015 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility | Journal of Pharmacology and Experimental Therapeutics
Inhibiting the proton pump: mechanisms, benefits, harms, and questions | BMC Medicine | Full Text
A Review of the Rational Administration of Gastric Protectants to Dogs and Cats ACVIM Consensus Statement • MSPCA-Angell
SEC Filing | Phathom Pharmaceuticals, Inc.
Vonoprazan Fumarate
